About Cerevasc
CereVasc is a medical device company that specializes in developing innovative solutions for the treatment of communicating hydrocephalus. The company's flagship product, the eShunt™ device, is designed to improve patient outcomes and redefine the way this condition is treated.
Communicating hydrocephalus is a condition that occurs when there is an imbalance between the production and absorption of cerebrospinal fluid (CSF) in the brain. This can lead to an accumulation of fluid, which can cause pressure on the brain and result in a range of symptoms such as headaches, nausea, vomiting, and cognitive impairment.
Traditionally, communicating hydrocephalus has been treated with shunt systems that rely on gravity or pressure differentials to regulate CSF flow. However, these systems are often associated with complications such as infection, blockage or malfunctioning.
The CereVasc eShunt™ device offers a new approach to treating communicating hydrocephalus by using an active pumping mechanism that regulates CSF flow based on real-time measurements of intracranial pressure (ICP). This allows for more precise control over CSF flow and reduces the risk of complications associated with traditional shunt systems.
The eShunt™ device consists of two components: an implantable pump unit and an external controller unit. The pump unit is implanted under the scalp and connected to a catheter that drains excess CSF from the brain into another part of the body where it can be absorbed. The external controller unit monitors ICP levels in real-time and adjusts pump settings accordingly.
One key advantage of this system is its ability to adapt to changes in ICP levels over time. For example, if ICP levels increase due to physical activity or other factors, the eShunt™ device will automatically adjust its pumping rate to maintain optimal CSF flow without causing excessive drainage or other complications.
Another advantage of this system is its potential for remote monitoring by healthcare providers. The external controller unit can be connected to a secure online platform that allows doctors to monitor patient data in real-time and make adjustments as needed. This could potentially reduce the need for frequent office visits and improve patient outcomes.
Overall, the CereVasc eShunt™ device represents a significant advancement in the treatment of communicating hydrocephalus. Its active pumping mechanism, real-time monitoring capabilities, and potential for remote monitoring make it a promising option for patients who suffer from this condition. As more research is conducted on this innovative technology, it is likely that we will see even more improvements in patient outcomes and quality of life.